
Artificial Heart Receives FDA Conditional Approval for Second Cohort of EFS Study
CARMAT announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to initiate the second cohort of its Early Feasibility Study (EFS) with Aeson® artificial heart in the United States. Stéphane Piat, Chief Executive …